Q-omics provides the consensus-scored RFT1 profile across patient tissues and cancer cell-line models. RFT1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RFT1 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, RFT1 protein abundance shows 19,367 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, BLCA, and GBM as cancer lineages where RFT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RFT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RFT1 survival associations across molecular data types. RFT1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RFT1 RNA expression–survival associations across cancer types. High RFT1 expression shows unfavorable associations in ACC, BLCA, LIHC, LGG and PAAD, but favorable associations in READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RFT1 RNA expression.
This table summarizes RFT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RFT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RFT1 shows lower tumor expression in THCA and higher tumor expression in BLCA, LIHC, COAD, KIRP and LUAD. The BLCA box plot shows higher RFT1 RNA expression in tumor versus normal tissue (log2 FC = +0.951, t-test p < 0.001).
This table shows molecular features associated with RFT1 in patient tissues and cancer cell lines. In patient samples, RFT1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RFT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
